Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2005
04/07/2005CA2530679A1 Compounds for treating angiogenesis
04/07/2005CA2527074A1 Antiangiogenic agents
04/07/2005CA2506282A1 Use of galanthamine and the derivatives thereof in the production of medicaments
04/06/2005EP1520856A1 Androgen receptor agonist
04/06/2005EP1520855A1 Thieno(2,3-b)pyridine derivatives useful as antagonists of gonadotropin releasing hormone
04/06/2005EP1520854A2 Aza-Spirocompounds for the treatment of pain
04/06/2005EP1520590A1 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
04/06/2005EP1520584A1 Composition for the activation of the immune system
04/06/2005EP1520583A2 NKT cell-activating agents containing alpha-glycosylceramides
04/06/2005EP1520582A2 Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
04/06/2005EP1520581A1 Composition based on a thiazolidinedione and metformin and its use
04/06/2005EP1520580A1 Creatine composition and use
04/06/2005EP1520579A1 Compositions for the treatment and prevention of cancer
04/06/2005EP1520050A2 Tr4/tr2 response elements
04/06/2005EP1520044A2 Chromosome 6 and 9 genes involved in premature canities
04/06/2005EP1520042A2 Chromosome 3, 5 and 11 genes involved in premature canities
04/06/2005EP1520021A2 Antisense modulation of lrh1 expression
04/06/2005EP1520015A2 Plant deoxyribonucleoside kinase enzymes and their use
04/06/2005EP1520003A1 Process for recovery of plant sterols from by-product of vegetable oil refining
04/06/2005EP1519962A1 Ester derivatives of hyaluronic acid for the preparation of hydrogel materials by photocuring
04/06/2005EP1519961A1 Low molecular weight oversulfated polysaccharide
04/06/2005EP1519956A2 Epha2 monoclonal antibodies and methods of use thereof
04/06/2005EP1519943A2 Hormone-based nitrogen monoxide donor compounds and use thereof in obstetrics and gynecology
04/06/2005EP1519940A1 Substituted aryl boronic acids, their preparation and their precursors
04/06/2005EP1519939A2 N-aryl diazaspiracyclic compounds and methods of preparation and use thereof
04/06/2005EP1519933A1 Quinuclidine amide derivatives
04/06/2005EP1519925A1 Oxazole derivatives and their use as insulin sensitizers
04/06/2005EP1519924A1 Difluorothioacetamides of oxazolidinones as antibacterial agents
04/06/2005EP1519923A1 Novel benzimidazol-2-one derivatives and their use
04/06/2005EP1519922A1 Di-aryl-substituted ethane pyridone pde4 inhibitors
04/06/2005EP1519920A1 Novel tetrahydropyridine derivatives as renin inhibitors
04/06/2005EP1519919A1 Indolin phenylsulfonamide derivatives
04/06/2005EP1519915A2 Tricyclic steroid hormone nuclear receptor modulators
04/06/2005EP1519908A2 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
04/06/2005EP1519754A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents
04/06/2005EP1519753A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor
04/06/2005EP1519752A1 Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors
04/06/2005EP1519751A2 Compositions comprising panthetine for the treatment of dyslipidemia
04/06/2005EP1519750A2 Oxygenating agents for enhancing host responses to microbial infections
04/06/2005EP1519744A2 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
04/06/2005EP1519743A1 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
04/06/2005EP1519737A2 Fibrin nanoparticles and uses thereof
04/06/2005EP1519735A2 Assays and implements for determining and modulating hsp90 binding activity
04/06/2005EP1519734A1 Ciclesonide-containing sterile aqueous suspension
04/06/2005EP1519733A1 Compositions for cancer therapy comprising saponins or sapogenins
04/06/2005EP1519732A1 Use of vasopeptidase inhibitors in the treatment of nephropathy
04/06/2005EP1519731A1 Combination of azelastine and steroids
04/06/2005EP1519730A1 Novel use of imidazotriazinones
04/06/2005EP1519729A1 Pyrrolotriazinone compounds and their use to treat diseases
04/06/2005EP1519728A1 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
04/06/2005EP1519727A1 4-(4-methylpiperazin-1-ylmethyl)-n- 4-methyl-3-(4-pyridin-3- yl)pyrimidin-2-ylamino)phenyl -benzamide for treating pulmon ary fibrosis
04/06/2005EP1519726A1 Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases
04/06/2005EP1519724A1 Fredericamycin derivatives as medicaments for treating tumours
04/06/2005EP1519723A1 Novel glucagon antagonists/inverse agonists
04/06/2005EP1519722A1 Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents
04/06/2005EP1519721A1 Polymer affinity matrix, a method for the production and use thereof
04/06/2005EP1519720A2 Novel formate salt of o-desmethyl-venlafaxine
04/06/2005EP1519719A1 Methods for the treatment of sinusitis
04/06/2005EP1519718A1 At least partially degradable films containing an active ingredient and method for the production thereof
04/06/2005EP1519717A1 Controlled release composition
04/06/2005EP1519716A1 Extended-release tablets comprising divalproex sodium
04/06/2005EP1519715A2 Nanoparticulate fibrate formulations
04/06/2005EP1519713A2 Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
04/06/2005EP1519711A1 Controlled-release pharmaceutical formulations
04/06/2005EP1519704A2 Spherical pellet containing a water-soluble active ingredient
04/06/2005EP1480627A4 Methods of reducing angiogenesis
04/06/2005EP1414817B1 substituted isoindoles and the use thereof
04/06/2005EP1406898B1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
04/06/2005EP1392656A4 Process for preparing chiral diol sulfones and dihydroxy acid hmg coa reductase inhibitors
04/06/2005EP1353909B1 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioidreceptor binding agents
04/06/2005EP1334086B1 Phenoxyphenyl alkane sulfonates
04/06/2005EP1321140B1 Ibuprofen solutions for capsule-filling and capsule preparations
04/06/2005EP1311258B1 Compositions containing hypotriglyceridemically active stilbenoids
04/06/2005EP1307455B1 Inhibitors of alpha-l beta-2 mediated cell adhesion
04/06/2005EP1299409B1 9.alpha.-chloro-6.alpha.-fluoro-17.alpha.-hydroxy-16-methyl-17-beta-methoxycarbonyl-androst-1,4-dienes esterified in position 17.alpha. by a cyclic acyl group
04/06/2005EP1289996B1 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
04/06/2005EP1278761B1 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
04/06/2005EP1257275B1 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
04/06/2005EP1251737B1 Compositions treated to inactivate infectious proteins
04/06/2005EP1248652B1 Stable aqueous deoxyfructosazine solution
04/06/2005EP1239840B1 Antiviral medication
04/06/2005EP1237936B1 Molecularly imprinted polymers produced by template polymerisation
04/06/2005EP1231918B1 Novel composition based on a thiazolidinedione and metformin and use
04/06/2005EP1227809B1 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
04/06/2005EP1218494B1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
04/06/2005EP1218357B1 Quinazoline derivatives
04/06/2005EP1214084B1 An anti-oxidant preparation based on plant extracts for the treatment of circulation and adiposity problems
04/06/2005EP1202975B1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
04/06/2005EP1140062B1 Treatment of asthma with mek inhibitors
04/06/2005EP1100509B1 Use of biogenic estrogen sulfamates for hormone replacement therapy
04/06/2005EP1090012A4 Inhibitors of prenyl-protein transferase
04/06/2005EP1090011A4 Inhibitors of prenyl-protein transferase
04/06/2005EP1077700B1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE
04/06/2005EP1040190B1 Serine proteinase inhibitors
04/06/2005EP1028733B1 Use of mixtures of active agents containing phytostenol for producing hypocholesteraemic preparations
04/06/2005EP1020459B1 Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives
04/06/2005EP1006964B1 Intrauterine chemical necrosing compositions and apparatus
04/06/2005EP0984930B1 2-indolinone derivatives as modulators of protein kinase activity
04/06/2005EP0966435B1 Aminoindan derivatives
04/06/2005EP0960096B1 Substituted beta-thiocarboxylic acids
1 ... 4730 4731 4732 4733 4734 4735 4736 4737 4738 4739 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 ... 7860